Friday, November 21, 2014 11:35:08 AM
Reckless would be to get in here without understanding how the 'Cides work, not understanding how the chemistry works, not understanding what it takes to get a production facility online and running, or what was required in order to get a good clinical trial underway.
Reckless would be to show up 'here' and not understand that there is always risk where there is potential reward,.... and to get overextended. Never bet the rent money and all that.
Reckless would be to ignore the history of missed deadlines here (which I don't ignore) and not realize that most of that 'fear' has already be subsumed in current shareprices as evidence of some of the risk that remains.
Reckless would be to look at the past only, and not realize that some significant things here haven't changed and for the better of late,.... and yet maintain the same 'song & dance' of often clearly incorrect information that gets distributed around here.
In other words,.... not reckless at all.
It does remain a reasonable possibility that the company will end up going nowhere,.... that's built into my investment strategy here. The probability of going 'nowhere' drops every time a milestone is met here.
But it also remains a bigger probability (IMO of course) that TOX will get completed with flying colors for Flucide, and the IND will get filed, and the Shelton plant will go online, and all the production limitations will get overcome, and even that some combination of ligands will work against Ebola,....
Those who do not see this,... probably should be invested elsewhere,....
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM